{'fraction_non_alphanumeric': 0.0267515923566879, 'fraction_numerical': 0.008917197452229299, 'mean_word_length': 5.717948717948718, 'pattern_counts': {'":': 0, '<': 0, '<?xml version=': 0, '>': 0, 'https://': 0, 'lorem ipsum': 0, 'www.': 0, 'xml': 0}, 'pii_count': 0, 'substrings_counts': 0, 'word_list_counts': {'cursed_substrings.json': 0, 'profanity_word_list.json': 0, 'sexual_word_list.json': 0, 'zh_pornsignals.json': 0}}
Prednisolone acetate-gentamicin combination following cataract surgery.

One-hundred-eleven patients participated in a 21-day, open-label study to evaluate the therapeutic efficacy and safety of a prednisolone acetate 1%-gentamicin 0.3% ophthalmic suspension to control inflammation and prevent infection after cataract surgery. Beginning the day after surgery, the medication was instilled qid for the next 21 days. No postoperative infection was noted, and postoperative inflammation, which was mild immediately after surgery, decreased steadily during follow-up. The results of this study suggest that a prednisolone acetate-gentamicin combination used for three weeks after cataract surgery is safe and has a positive therapeutic effect on postoperative inflammation and infection.